• Title/Summary/Keyword: 악성 흑색종

Search Result 83, Processing Time 0.036 seconds

The Significance of Sentinel Node Biopsy in Malignant Melanoma and Squamous Cell Carcinoma of Lower Extremities (하지에 발생한 악성흑색종 및 편평상피세포암에서 소속 림프절 생검의 의미)

  • Kim, Jae-Do;Lee, Gun-Woo;Kwon, Young-Ho;Chung, So-Hak
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.16 no.2
    • /
    • pp.69-73
    • /
    • 2010
  • Purpose: Sentinel lymph node (SLNB) is the first confronted lymph node from primary lesion of tumor through lymphatic drainage, which is important for determining early metastasis and setting guidelines for treatment. We reported significant of sentinel lymph node biopsy in malignant melanoma (MM) and squamous cell carcinoma (SCC) of lower extremities. Materials and Methods: Twenty-five cases of surgically treatment and being possible for follow up more than 1 year among the patients who were diagnosed as MM and SCC in this institution from Sep. 2005 to Jan. 2009, and 10 cases of them were performed SLNB. Average age was 64 years old, and 15 cases of male and 10 cases of female were in this group. Results: 3 years overall survival rate was 100% and 3 years disease-free survival rate was 76%. Metastasis occurred in total 6 patients, 4 cases of inguinal lymph nodes, 1 case of soft tissue around knee, 1 case of left achilles tendon. In 15 cases of not performing SLNB, overall survival rate was 93.3% and disease-free survival rate was 73.3%. In 10 cases of performing SLNB, overall survival rate was 100% and disease-free survival rate was 90%. And only 1 case showed positive finding in the biopsy, and none of the 10 cases showed metastasis in follow-up. Conclusion: SLNB leads simpler and less complications compared to prior elective lymph node dissection, and shows high degree of accuracy. Throughout the SLNB, setting guidelines for treatment by accurate staging is thought to be helpful for increasing the survival rate in the patient with MM and SCC.

MALIGNANT MELANOMA OF THE ORAL CAVITY;REPORT OF TWO CASES (구강내 발생한 악성 흑색종)

  • Yang, Dong-Kyu;Chung, In-Kyo;Kim, Jong-Ryoul;Choi, Kab-Rim;Park, Sang-Jun;Moon, One-Ryong
    • Maxillofacial Plastic and Reconstructive Surgery
    • /
    • v.12 no.1
    • /
    • pp.135-141
    • /
    • 1990
  • Malignant Melanoma refers to a malignant neoplasm of melanocytes. Primary malignant melanoma of oral cavity is rare. Most frequent site of primary oral malignant melanoma are palate & gingiva. We have experienced 2 cases of malignant melanoma of the mouth. In one case, we performed wide surgical excision which was followed by chemotherapy with DTIC. In the other case, performed wide surgical excision only. There is no evidence of recurrence or of metastasis of the lesions 22 months, 12 months after operation, respectively.

  • PDF

Clinical Application of $^{18}F-FDG$ PET in Malignant Melanoma (악성 흑색종에서 $^{18}F-FDG$ PET의 임상 이용)

  • Yoon, Joon-Kee
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.42 no.sup1
    • /
    • pp.140-148
    • /
    • 2008
  • $^{18}F-FDG$ PET showed a high sensitivity and specificity in the initial staging of malignant melanoma, and it also predicted the prognosis correctly. In addition, it had a higher sensitivity and specificity in the detection of recurrence and restaging than conventional imaging modalities. Meanwhile, there's less clinical evidence to support the use of $^{18}F-FDG$ PET in the response evaluation for chemotherapy and the diagnosis/differential diagnosis of malignant melanoma.

암종증이 동반된 두경부 악성 흑색종 1예

  • Jeong, Hui-Cheol;Ra, Seon-Yeong;Park, Jun-O;Jo, Jae-Yong;Lee, Jong-In;Yu, Nae-Chun;Jeong, Hyeon-Cheol;Kim, Ju-Hang;No, Jae-Gyeong;Min, Jin-Sik;Kim, Byeong-Su
    • 대한두경부종양학회:학술대회논문집
    • /
    • 1995.11a
    • /
    • pp.217.1-217.1
    • /
    • 1995
  • PDF

The Analysis of Post Operative Treatment of Malignant Melanoma Using High Dose Interferon-${\alpha}2b$ Immunotherapy: Preliminary Report (악성흑색종 환자군에서 수술적 치료 후 시행한 고용량 인터페론-${\alpha}2b$ 면역요법에 의한 보조적 치료 결과 분석: 예비보고)

  • Chung, So Hak;Jo, Hyun Ik
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.18 no.2
    • /
    • pp.78-82
    • /
    • 2012
  • Purpose: Interferon-${\alpha}2b$ using immunotherapy of malignant melanoma is known to increase the microscopic enemies that remain after surgical resection of the tumor to prevent recurrence, disease-free survival and overall survival. Authors in patients with malignant melanoma after surgical resection and high-dose interferon-${\alpha}$ immunotherapy treated group of disease-free survival and overall survival compared with the results of the treatment of immune therapy to a preliminary report. Materials and Methods: From February 2010 to October 2012 at our institution between being diagnosed with malignant melanoma after surgical immunotherapy treated patients were analyzed. Patients was evaluated using the stage AJCC stage IIA 3 cases, IIB 1 cases, IV 1 were as follows. Follow-up period of at least 7 months, and a maximum of 32 months. As maintenance therapy after the first induction therapy group underwent immunotherapy interferon-${\alpha}$ of body-surface area per 200,000 IU five times in a week for 4 weeks sedentary and body surface area a total of 48 weeks per week to 100,000 IU three times subcutaneously. These patients for local recurrence and metastases, and distant metastasis were investigated disease-free survival was investigated. Results: Interferon-evaluation through follow-up chest computed tomography (CT) and positron emission computed tomography (PET CT) in patients who underwent the ${\alpha}$ immunotherapy results above both local recurrence and metastases without evidence of distant metastases. Conclusion: The high-dose ${\alpha}2b$ immunotherapy performed in patients to prevent the local recurrence of the tumor and metastasis to the current or future ultimate survival and disease-free survival improvement achieved is additional study and follow-up will be needed.

A case of congenital neurocutaneous melanosis (선천성 신경피부멜라닌증 1례)

  • Ha, Sang Kyun;Lee, Jae Myoung;Kim, Eun Ryoung;Hwang, Ho;Lee, Hong Tak
    • Clinical and Experimental Pediatrics
    • /
    • v.49 no.2
    • /
    • pp.212-216
    • /
    • 2006
  • Neurocutaneous melanosis is a rare congenital syndrome characterized by the presence of large or multiple congenital melanocytic nevi and benign pigment cell tumors of the leptomeninges. Neurocutaneous melanosis is thought to represent an error in the morphogenesis of embryonal neuroectoderm. We experienced a neonate who presented with giant, dark colored pigmented nevi covering chest, abdomen, neck and arms, with satellite lesions. Magnetic resonance image showed a nodular hyperintense lesion in the amygdala of the right temporal lobe, and T1-weighted images showed hyperintensities in the adjacent leptomeninges. We report a rare case of neurocutaneous melanosis with a brief review of related literature.

Tumors of the Foot and Ankle (족부 및 족관절에 발생한 종양)

  • Shin, Kyoo-Ho;Park, Hong-Jun;Kim, Jong-Min;Hahn, Soo-Bong;Kang, Eung-Shick
    • The Journal of the Korean bone and joint tumor society
    • /
    • v.6 no.2
    • /
    • pp.69-76
    • /
    • 2000
  • Purpose : Tumors of the foot and ankle are uncommon compared with those arising in the other sites, and the malignant tumors are rare. We analyzed the data of patients who have been diagnosed as having a tumor of the foot and ankle. Materials and Methods : Between 1989 and 1998, we treated 72 patients and analyzed on their clinical characteristics retrospectively. Results : Fifty-three cases were benign. Included are 30 cases of soft tissue tumor and 23 cases of bone tumor. Malignant tumor was in 19 cases (26%), including 17 cases of soft tissue tumor, one cases of metastatic tumor. The most common benign tumor was fibroma in soft tissue and osteochondroma in bone. Malignant melanoma was the most common malignant tumor of the foot (7 cases). The predilection site for benign tumors was around toes while for the malignant tumor mostly arises in the heel. Among 19 malignant tumors, local recurrence developed in 3 cases and the distant metastasis occurred in 8 cases. Conclusion : The ratio of malignant tumor and metastasis was high. Therefore, when we faced with a tumor of the foot and ankle, the histopathologic confirmation is essential through biopsy before the definite initial treatment.

  • PDF

Anti-Cancer Effect of Ursolic Acid in Melanoma Cell A375SM and A375P (Ursolic acid의 악성 흑색종 세포주 A375SM과 A375P에서의 항암효능)

  • Woo, Joong-Seok;Kim, Na-Won;Lee, Jin-Gyu;Kim, Jae-Hyuk;Lim, Da-Young;Kang, Shin-Woo;Kim, Sung-Hyun;Yoo, Eun-Seon;Lee, Jae-Han;Han, So-Hee;Park, Young-Seok;Kim, Byeong-Soo;Kim, Sang-Ki;Park, Byung-Kwon;Jung, Ji-Youn
    • Journal of Food Hygiene and Safety
    • /
    • v.34 no.2
    • /
    • pp.183-190
    • /
    • 2019
  • Ursolic acid is recognized for various effects such as anti-cancer, antioxidant, and anti-inflammatory activity. In this study, we confirmed the anti-cancer effect of ursolic acid on human melanoma cancer cells, A375SM and A375P. Survival rate of the melanoma cells was confirmed by MTT assay and the proliferation rate was confirmed by wound healing assay. The rate of apoptotic bodies was confirmed by DAPI staining, and apoptosis rate was confirmed by flow cytometry. The induction of apoptosis protein was examined by western blotting according to the concentration of ursolic acid in melanoma cells. The survival and proliferation rates of melanoma cells were decreased according to the treatment concentrations of ursolic acid. DAPI staining showed that chromosomal condensation of melanoma cells was increased with increasing concentrations of ursolic acid, and increased apoptosis rate of melanoma cells by ursolic acid was confirmed by flow cytometry. We also confirmed by western blotting that cleaved-PARP and Bax were increased and Bcl-2 was decreased at $12{\mu}M$ concentration of uricolic acid in melanoma cells. This study was carried out at low concentrations of ursolic acid, 0 to $20{\mu}M$, and analyzed 24 h after treatment. As a result of this study, it is thought that ursolic acid has the anti-cancer effect through the regulation of apoptosis-related proteins in melanoma cells A375SM and A375P.

마우스 및 랫트의 정상조직과 종양성 병변에서의 Nucleolar Organizer Regions (NORs)

  • 김성호;김태환;장자준
    • Environmental Mutagens and Carcinogens
    • /
    • v.10 no.2
    • /
    • pp.135-145
    • /
    • 1990
  • Silver-binding nucleolar organizer regions (Ag-NORs)염색법을 이용하여 in vivo 및 in vitro에서 발암과정과 관련된 세포증식능을 검토하였다. A/J마우스에 benzo (a) pyrene을 투여하여 유발된 폐선종, 폐선암 및 Sprague-Dawley랫트에 dimethylbenz (a) anthracene투여에 의해 발생된 유선의 선암세포에서 Ag-NORs의 염색상태를 정상 조직과 비교하여 또한 정상마우스 섬유모세포인 NIH3T3에서의 Ag-NORs의 수 및 DNA 증식 억제물질인 caffeine에 의한 변화를 관찰하였다. 은친화성 NOR과련 단백질은 핵내 흑색의 반점으로 나타났으며 정상 폐조직의 세포당 Ag-NORs 수치는 0.87+0.01였으며 양성종양인 폐선종세포 및 악성종양인 폐선암세포에서는 각각 2.33+0.02, 2.56+0.45 정상 유선조직의 세포당 Ag-NORs수치는 1.21+0.16였으며 악성종양인 선암세포는 3.91+0.11로써 종양성 병변에서 유의한 증가를 보였다 (P<0.005).

  • PDF

Ginsenoside Rg3 Induces Apoptosis in B16F10 Melanoma Cells (ginsenoside Rg3에 의한 B16F10 흑색종 세포의 세포사멸 유도)

  • Lee, Seul Gi;Kim, Byung Soo;Nam, Ju-Ock
    • Journal of Life Science
    • /
    • v.24 no.9
    • /
    • pp.1001-1005
    • /
    • 2014
  • Ginsenoside Rg3 is one of the active ingredients extracted from red ginseng, and it is an effective chemical component of the human body and well known in herbal medicine as a restorative agent. Several studies have shown that Rg3 has a potent anti-tumor effect on various cancer cell lines. However, Rg3-induced apoptosis in B16F10 melanoma cancer cells is not well understood. In the present study, we tested whether ginsenoside Rg3 could induce apoptosis in B16F10 melanoma cells. We found that Rg3 could inhibit B16F10 melanoma cell viability in a dose-dependent manner, but not normal cells, such as EA.hy.926 and NIH3T3 cells. We also found that Rg3 could induce apoptosis in B16F10 melanoma cells using tunnel-staining assay in a dose-dependent manner. Rg3 treatment induces the phosphorylation of p38 and the expression of Bax, but it inhibits the expressions of the phosphorylation of focal adhesion kinase Bcl2 and pro-caspase3. Taken together, our data suggest that Rg3 could be useful as an anti-cancer agent in B16F10 melanoma cells.